Format

Send to

Choose Destination
Cell Death Differ. 2015 Apr;22(4):549-59. doi: 10.1038/cdd.2015.3. Epub 2015 Feb 6.

The role of CD95 and CD95 ligand in cancer.

Author information

1
Division Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Erratum in

Abstract

CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy.

PMID:
25656654
PMCID:
PMC4356349
DOI:
10.1038/cdd.2015.3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center